Novo Nordisk is leveraging artificial intelligence to overhaul its drug discovery pipeline. The Danish pharmaceutical giant finalized a partnership with Anthropic to integrate the Claude AI model, aiming to streamline the creation of new medicines through advanced computational analysis. This collaboration highlights the growing reliance on machine learning to compress traditional research timelines.

Simultaneously, Reckitt Benckiser is pivoting its operational strategy to capture greater market share in the United States. The British manufacturer behind Mucinex and Lysol intends to scale up local product development and manufacturing infrastructure. By shortening supply chains and increasing domestic capacity, the company seeks to improve its agility in responding to rapid changes in consumer demand patterns.